Human normal immunoglobulins - supply shortage
Ongoing
human normal immunoglobulins
Shortage
Human
Shortage information
Human normal immunoglobulins are highly purified proteins extracted from donated human blood. They contain mainly immunoglobulin G (IgG), a class of antibody with a wide range of activity against organisms that can cause infection.
Human normal immunoglobulins are used to treat a range of diseases. These include primary immunodeficiency disorders (PID), secondary immunodeficiencies (SID) and immunomodulatory diseases.
There have been shortages of several medicines containing human normal immunoglobulins given by injection or infusion into a vein or under the skin. The causes of the shortages are multifactorial and include an unexpected increase in demand. These shortages affect medicines authorised across the EU/EEA as well as several medicines authorised at national level. They are expected to last until June 2026.
The shortages are not related to a quality defect of the products or a safety issue.
The shortage affects a number of EU Member States. For up-to-date information about the status of a medicine shortage in a particular EU/EEA Member State, consult the national shortage register or contact the national competent authority.
EMA’s SPOC working party is closely monitoring the supply situation and engaging with the marketing authorisation holders to identify measures to mitigate the impact of the supply shortage.
The SPOC working party is responsible for monitoring and reporting events that could affect the supply of medicines in the EU. Summaries of the SPOC working party meetings can be found here: Medicine Shortages SPOC Working Party meetings.
- In case of shortage, you should follow local and national guidance which may include prioritisation of indications or use of alternative treatment options.
- For additional information consult your country’s shortage register or contact your national competent authority.
- If the human normal immunoglobulin medicine you are using is not available, your doctor will discuss suitable treatment alternatives with you, in line with the national guidance in your country.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Key facts
- Medicines affected
- Human normal immunoglobulins
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- human normal immunoglobulins
- Therapeutic area (MESH)
- Primary Immunodeficiency Diseases
- Immunologic Deficiency Syndromes
- Pharmaceutical forms affected
- Solution for injection/infusion
- Availability of alternatives
- Yes
Key dates
- Expected resolution
- To last until June 2026.
- First published
- Last updated